Sarepta Therapeutics, Inc. (SRPT) Investor Relations Documents

Sarepta Therapeutics, Inc. (SRPT) investor relations documents from the company's IR site: 3 presentations, 37 press releases; latest deck 2026-05-06. Read in-app with summaries. First-party data.

Q1 2026 Earnings Presentation: Sarepta Therapeutics Q1 2026 financial results report $331 million in product revenue and reiterate full-year 2026 guidance of $1.2 billion to $1.4 billion.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releasePress release
2026-08-05Press releaseSarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
2026-07-29Press releasePress release
2026-07-29Press releaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-27Press releasePress release
2026-07-27Press releaseSarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
2026-07-22Press releasePress release
2026-07-22Press releaseSarepta Therapeutics to Announce Second Quarter 2026 Financial Results
2026-06-30Press releasePress release
2026-06-30Press releasePress release
2026-06-30Press releaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-30Press releaseSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
2026-06-01Press releasePress release
2026-06-01Press releaseSarepta Therapeutics to Participate in Upcoming Investor Conferences
2026-05-13Press releasePress release
2026-05-13Press releaseSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
2026-05-06Earnings deckQ1 2026 Earnings Presentation
2026-05-06Press releasePress release
2026-05-06Press releaseSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
2026-04-22Press releasePress release
2026-04-22Press releaseSarepta Therapeutics to Announce First Quarter 2026 Financial Results
2026-03-31Press releasePress release
2026-03-31Press releaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-25PresentationPreliminary Phase 1_2 Clinical Data Readout for DM1 and FSHD Programs Presentation
2026-03-25Press releasePress release
2026-03-25Press releaseSarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
2026-03-24Press releasePress release
2026-03-24Press releaseSarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
2026-03-19Press releasePress release
2026-03-19Press releaseSarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
2026-03-16Press releaseSarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression
2026-03-16Press releaseSRPT Press Release - ENDEAVOR cohort 8 Enrollment (Mar 16 2026)_updated.pdf
2026-03-11PresentationMDA 2026 EMBARK 3yr vs EC Presentation
2026-02-27Press releasePress release
2026-02-27Press releaseSarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
2026-02-26Press releasePress release
2026-02-26Press releaseSarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Mus
2026-02-25Press releasePress release
2026-02-25Press releaseSarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
2026-02-24Press releasePress release

SRPT overview · SRPT earnings · SRPT financials · SRPT KPIs · SRPT documents · SRPT ownership · SRPT peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.